EL

PMGC Holdings Inc.

ELABHealthcareNASDAQ

Biotechnology · Last scanned Sep 7, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$590,084
Net Income
-$7.7M
-24.0% YoY
EBITDA
-$7.4M
-126.3% YoY
Free Cash Flow
-$4.1M

Scan Results

Daily timeframe
3 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3 RSI OversoldRSI 22.7, below 30, stock may be oversold
Sep 2 RSI OversoldRSI 21.9, below 30, stock may be oversold
About PMGC Holdings Inc.

Part of the healthcare sector, PMGC Holdings Inc. (ELAB) is listed under Biotechnology. Valued at $4.2M, ELAB is a micro-cap name in its sector. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining.

Where ELAB stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, ELAB finished 85.04% below its 150-day moving average ($34.03) and 97.40% below its 200-day moving average ($195.80). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is ELAB overbought or oversold?

At the September 3, 2026 close, ELAB's RSI(14) was 22.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$4.2M
EPS$-1830.96
Beta-0.30
52W Change-99.5%
ROE-105.2%
Analysis

With $19.0M in cash and $14.2M in debt, ELAB maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$4.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -105.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $766K (2022) to $590K (2025), a 23% decline worth watching.

With a beta below 0.7, PMGC Holdings Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for PMGC Holdings Inc. and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms